discontinuation of glucagon-like peptide-1 receptor agonists Individuals are likely to regain weight after discontinuing GLP1 RA therapy - New studies on GLP-1 Discontinuation of GLP-1RA treatment leads to weight regain Understanding the Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists

New studies on GLP-1 The discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is a critical issue with significant clinical, policy, and equity implications. These medications, which mimic the action of the naturally occurring glucagon-like peptide-1 (GLP) hormone, have demonstrated remarkable efficacy in managing type 2 diabetes and promoting weight loss. However, a substantial percentage of patients discontinue these therapies, often within the first year of treatment, leading to a potential reversal of benefits and a weight gain after withdrawal or discontinuation.

Prevalence of Discontinuation:

Real-world data consistently reveal high discontinuation rates for GLP-1 RAs. Studies indicate that anywhere from 50% to 75% of patients stop treatment within a year, with some reporting one-year discontinuation rates as high as 74%作者：D Do·2024·被引用次数：137—One study found a 12-monthdiscontinuationof 45.2% among patients with T2D. In this study, we estimated the prevalence ofGLP-1 agonist.... Specific figures highlight this trend: 26.2% at three months, 30.8% at six months, and 36.Real-world weight change, adherence, and discontinuation ...5% at 12 monthsFDA's Concerns with Unapproved GLP-1 Drugs Used for .... For individuals with type 2 diabetes, adherence can be a challenge, with one study noting that 70.1% discontinued therapy by 24 months.作者：D Do·2024·被引用次数：137—One study found a 12-monthdiscontinuationof 45.2% among patients with T2D. In this study, we estimated the prevalence ofGLP-1 agonist... Notably, the discontinuation of GLP-1RA treatment leads to weight regain, a phenomenon observed regardless of lifestyle interventions.A new study reveals thatmost patients discontinue GLP-1 receptor agonists within a year, with significantly higher dropout rates among those using them for ... This is particularly pronounced in individuals with overweight and obesity who do not have type 2 diabetes, where discontinuation rates are higher.

Factors Influencing Discontinuation:

While the exact reasons for discontinuation vary, several factors contribute. The cessation of GLP-1 RA therapy often leads to a predictable, though decelerating, pattern of weight regain, which may eventually plateau below pre-treatment levels.A new study reveals thatmost patients discontinue GLP-1 receptor agonists within a year, with significantly higher dropout rates among those using them for ... This weight gain after GLP-1 discontinuation is a primary concern for many patients.5天前—A new analysis suggests that the health gains achieved with weight loss medications may not last once treatment ends, with body weight and ... Furthermore, the loss of other benefits, such as improved glycemic control and reduced cardiovascular risk, can also influence a patient's decision to stop treatment. The availability of newer glucagon-like peptide-1 receptor agonists and their efficacy in obesity and diabetes management continues to be a focus of research.

Clinical and Policy Considerations:

The implications of discontinuation extend beyond individual patient outcomes. From a policy perspective, understanding GLP-1 RA discontinuation is crucial for optimizing treatment guidelines and ensuring equitable accessTreatment discontinuation among users of GLP-1 receptor .... The FDA's concerns with unapproved GLP-1 drugs used for weight loss underscore the importance of appropriate prescribing and patient selectionDiscontinuing glucagon-like peptide-1 receptor agonists .... The World Health Organization (WHO) issues global guideline on the use of GLP-1 receptor agonists, emphasizing their role in blood sugar control, weight loss, and reducing the risk of heart and kidney disease作者：D Do·2024·被引用次数：137—One study found a 12-monthdiscontinuationof 45.2% among patients with T2D. In this study, we estimated the prevalence ofGLP-1 agonist....

Reinitiation and Future Directions:

The concept of reinitiation of GLP-1 receptor agonists is also being explored. Discontinuation is the first date a patient is 60 days or more without any GLP-1 RA medication on hand, and understanding the timeline and effectiveness of restarting therapy is an area of ongoing research. While the benefits of GLP-1 agonists in managing chronic conditions are undeniable, addressing the challenges associated with discontinuation is paramount.Real-World Adherence and Discontinuation of Glucagon ... This includes exploring strategies to improve adherence, manage weight regain post-cessation, and ensure that patients can sustain the health gains achieved with these powerful medications2024年11月13日—This Viewpoint discusses the health benefits ofglucagon-like peptide-1 receptor agonists(GLP-1 RAs); summarizes the clinical, policy, and equity implications .... Research into novel agonist compounds, such as retatrutide, which targets glucagon receptors alongside like peptide 1 and glucose-dependent insulinotropic polypeptide receptors, offers potential future avenues for treatment.

The landscape of glucagon-like peptide-1 receptor agonists for obesity and diabetes is rapidly evolving. Continued research into adherence, long-term outcomes, and the management of discontinuation effects is essential to maximize the therapeutic potential of this important drug class. The focus remains on understanding the full trajectory of weight regain after cessation of GLP-1 agonist therapy and developing strategies to mitigate these effects.